Survival Following Stereotactic Radiotherapy for Recurrent High Grade Gliomas

被引：5

作者：

Ertas, Gulcin ^{[1
]}

Ucer, Ali R. ^{[1
]}

Guney, Yildiz Y. ^{[1
]}

Avci, Gulhan G. ^{[1
]}

Altundag, M. Bedri ^{[1
]}

Abanuz, Hayati ^{[1
]}

Demirkasimoglu, Atilla ^{[1
]}

Calikoglu, Tamer ^{[1
]}

机构：

[1] Ankara Oncol Training & Res Hosp, Dept Radiat Oncol, Ankara, Turkey

来源：

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI | 2014年 / 24卷 / 04期

关键词：

Cyberknife; Glioma; Stereotactic radiotherapy; DIAGNOSED GLIOBLASTOMA-MULTIFORME; GAMMA-KNIFE RADIOSURGERY; MALIGNANT GLIOMA; RADIATION-THERAPY; PHASE-II; CHEMOTHERAPY; TEMOZOLOMIDE; EFFICACY;

D O I：

10.4999/uhod.14444

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We aimed to report our stereotactic radiotherapy experience with Cyberknife (Accuray, Inc., Sunnyvale, CA, USA) for patients with recurrent high grade glial tumor. Forty-two patients with histologically proven malign glioma (30 glioblastoma, 12 anaplastic astrocytoma) and also treated with previous conventional fractioned radiotherapy underwent stereotactic radiotherapy via Cyberknife for their recurrent tumor in Ankara Oncology Hospital between July 2009-and September 2012. The median follow up time was 30 months (range, 8-144 months) after diagnosis and 10 months (range, 1-38 months) from stereotactic radiotherapy (SRT). The median survival from SRT are 8 months for glioblastoma patients and 11 months for grade 3 malign glioma patients (p= 0.157). The median survival from SRT are 9 months and 11 months in patients given chemotherapy and not given, respectively (p= 0.436). The median survival from SRT are 10 months in patients reoperated and 9 months not reoperated (p= 0.827). Stereotactic radiotherapy is an effective treatment modality in patients with recurrent glial tumor.

引用

页码：233 / 238

页数：6

共 22 条

[1] Image-guided robotic radiosurgery [J].

Adler, JR ;

Murphy, MJ ;

Chang, SD ;

Hancock, SL .

NEUROSURGERY, 1999, 44 (06) :1299-1306

[2]

Afra D, 2002, LANCET, V359, P1011

[3] Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme [J].

Athanassiou, H ;

Synodinou, M ;

Maragoudakis, E ;

Paraskevaidis, M ;

Verigos, C ;

Misailidou, D ;

Antonadou, D ;

Saris, G ;

Beroukas, K ;

Karageorgis, P .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) :2372-2377

[4]

Biswas T, 2009, RADIAT ONCOL, V17, P4

[5] PLACEBO-CONTROLLED TRIAL OF SAFETY AND EFFICACY OF INTRAOPERATIVE CONTROLLED DELIVERY BY BIODEGRADABLE POLYMERS OF CHEMOTHERAPY FOR RECURRENT GLIOMAS [J].

BREM, H ;

PIANTADOSI, S ;

BURGER, PC ;

WALKER, M ;

SELKER, R ;

VICK, NA ;

BLACK, K ;

SISTI, M ;

BREM, S ;

MOHR, G ;

MULLER, P ;

MORAWETZ, R ;

SCHOLD, SC .

LANCET, 1995, 345 (8956) :1008-1012

[6] Hypofractionated Stereotactic Reirradiation of Recurrent Glioblastomas [J].

Fokas, Emmanouil ;

Wacker, Ulrich ;

Gross, Markus W. ;

Henzel, Martin ;

Encheva, Elitsa ;

Engenhart-Cabillic, Rita .

STRAHLENTHERAPIE UND ONKOLOGIE, 2009, 185 (04) :235-240

[7]

Hess K R, 1999, Neuro Oncol, V1, P282, DOI 10.1093/neuonc/1.4.282

[8] Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas [J].

Kong, Doo-Sik ;

Lee, Jung-Il ;

Park, Kwan ;

Kim, Jong Hyun ;

Lim, Do-Hoon ;

Nam, Do-Hyun .

CANCER, 2008, 112 (09) :2046-2051

[9] Phase II study of high central dose gamma knife radiosurgery and marimastat in patients with recurrent malignant glioma [J].

Larson, DA ;

Prados, M ;

Lamborn, KR ;

Smith, V ;

Sneed, PK ;

Chang, S ;

Nicholas, KM ;

Wara, WM ;

Devriendt, D ;

Kunwar, S ;

Berger, M ;

McDermott, MW .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 54 (05) :1397-1404

[10] Survival following CyberKnife radiosurgery and hypofractionated radiotherapy for newly diagnosed glioblastoma multiforme [J].

Lipani, John D. ;

Jackson, Paul S. ;

Soltys, Scott G. ;

Sato, Kengo ;

Adler, John R. .

TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2008, 7 (03) :249-255

← 1 2 3 →